search
Back to results

Intermittent Energy Restriction and Chewing on Neural Stem Cell Ageing and Adult Hippocampal Neurogenesis Associated Cognition (ChANgE)

Primary Purpose

Aging, Cognitive Decline

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Intermittent Energy Restriction
Chewing
Chewing + Intermittent Energy Restriction
Sponsored by
King's College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Aging focused on measuring Intermittent fasting, Adult hippocampal neurogenesis, Mastication, Pattern separation, Recognition memory, Klotho

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Male and female subjects.
  • 60+ years of age at the time of consent.
  • BMI 25-35.

Exclusion Criteria:

  • Subject is unable to understand the participant information sheet.
  • Subject is unable to understand and/or completely perform the cognitive testing.
  • Chews more than 3 sticks of gum per month, including nicotine replacement gum.
  • Unable to provide written informed consent.
  • Impaired vision that is not corrected.
  • Does not agree to maintain their habitual exercise routine.
  • Is not in general good health on the basis of medical history.
  • Unwilling to chew gum for 3 times a day for 12 weeks.
  • Unwilling to maintain an intermittent fasting diet regime.
  • Unwilling to have blood taken.
  • History of or are currently diagnosed with a significant psychiatric disorder (e.g. schizophrenia, anxiety, PTSD).
  • Subject has any neurological disorder that could produce cognitive deterioration (e.g. Alzheimer's disease, Parkinson's disease, stroke).
  • History of traumatic brain injury, stroke or any other medical conditions causing cognitive impairment.
  • Has uncontrolled epilepsy or is prone to fainting.
  • Participated in a weight management drug trial in previous 3 months.
  • Has undergone bariatric surgery.
  • Known or suspected of alcohol abuse defined as >14 drinks per week (1 drink = 1 pint of beer, 1 large glass of wine or 50ml spirit).
  • Gastrointestinal or liver disease.
  • Subject has a sleep disorder or an occupation where sleep during the overnight hours is irregular.
  • Subjects taking the following prescription medications: Donepezil (Aricept), Galantamine (Reminyl), Rivastigmine (Exelon), Tacrine (Cognex), Bethanechol (Urecholine), Memantine (Namenda) Selegiline (Eldepryl) or any other medication for cognitive impairment.
  • Subject has a known sensitivity to the study product.
  • Individual has a condition the chief investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, might confound the interpretation of study results or put the subject at undue risk.

Sites / Locations

  • Diabetes & Nutritional Sciences Division, King's College London, Franklin-Wilkins Building, 150 Stamford St

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

No Intervention

Arm Label

Intermittent Energy Restriction

Chewing

Chewing + Intermittent Energy Restriction

Control

Arm Description

Dietary intervention: Intermittent energy restriction

Mastication intervention: chewing

Dietary and mastication intervention: Intermittent energy restriction and chewing

No intervention: Control

Outcomes

Primary Outcome Measures

Serum Klotho concentration
Anti-ageing longevity protein
Serum Klotho concentration
Anti-ageing longevity protein
Serum Klotho concentration
Anti-ageing longevity protein
Mnemonic Similarity Task
Neurogenesis-associated cognition
Mnemonic Similarity Task
Neurogenesis-associated cognition

Secondary Outcome Measures

Body weight
Body weight
Body weight
Body fat percentage
Body fat percentage
Body fat percentage
Body Mass Index
Body Mass Index
Body Mass Index
Waist circumference
Waist circumference
Waist circumference
Hip circumference
Hip circumference
Hip circumference
Patient Health Questionnaire
Questionnaire
Patient Health Questionnaire
Questionnaire
Patient Health Questionnaire
Questionnaire
Zung Self-Rating Anxiety Scale
Questionnaire - Scale can be scored from 20 (normal) to 80 (extreme anxiety levels). The total score is reported.
Zung Self-Rating Anxiety Scale
Questionnaire
Zung Self-Rating Anxiety Scale
Questionnaire
Pittsburgh Sleep Quality Index
Questionnaire
Pittsburgh Sleep Quality Index
Questionnaire
Pittsburgh Sleep Quality Index
Questionnaire
Plasma glucose concentration
Fasting
Plasma glucose concentration
Fasting
Plasma glucose concentration
Fasting
Cholesterol
Fasting
Cholesterol
Fasting
Cholesterol
Fasting
Triglycerides
Fasting
Triglycerides
Fasting
Triglycerides
Fasting
High Density Lipoprotein
Fasting
High Density Lipoprotein
Fasting
High Density Lipoprotein
Fasting
Low Density Lipoprotein
Fasting
Low Density Lipoprotein
Fasting
Low Density Lipoprotein
Fasting
Total/HDL Cholesterol Ratio
Fasting
Total/HDL Cholesterol Ratio
Fasting
Total/HDL Cholesterol Ratio
Fasting
Plasma adiponectin concentration
Fasting
Plasma adiponectin concentration
Fasting
Plasma adiponectin concentration
Fasting
Plasma leptin concentration
Fasting
Plasma leptin concentration
Fasting
Plasma leptin concentration
Fasting
Plasma beta-hydroxybutrate concentration
Fasting
Plasma beta-hydroxybutrate concentration
Fasting
Plasma beta-hydroxybutrate concentration
Fasting
Plasma total cholesterol concentration
Fasting
Plasma total cholesterol concentration
Fasting
Plasma total cholesterol concentration
Fasting
Plasma low density lipoprotein (LDL) cholesterol concentration
Fasting
Plasma LDL cholesterol concentration
Fasting
Plasma LDL cholesterol concentration
Fasting
Plasma high density lipoprotein (HDL) cholesterol concentration
Fasting
Plasma HDL cholesterol concentration
Fasting
Plasma HDL cholesterol concentration
Fasting
Plasma triglyceride concentration
Fasting
Plasma triglyceride concentration
Fasting
Plasma triglyceride concentration
Fasting
Plasma total cholesterol:HDL cholesterol ratio
Fasting
Plasma total cholesterol:HDL cholesterol ratio
Fasting
Plasma total cholesterol:HDL cholesterol ratio
Fasting

Full Information

First Posted
February 23, 2018
Last Updated
February 17, 2021
Sponsor
King's College London
Collaborators
Medical Research Council, Mars, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03457870
Brief Title
Intermittent Energy Restriction and Chewing on Neural Stem Cell Ageing and Adult Hippocampal Neurogenesis Associated Cognition
Acronym
ChANgE
Official Title
Investigating the Impact of Intermittent Energy Restriction and Chewing on Neural Stem Cell Ageing and Adult Hippocampal Neurogenesis: The ChANgE Study
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
April 18, 2018 (Actual)
Primary Completion Date
March 23, 2020 (Actual)
Study Completion Date
March 23, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King's College London
Collaborators
Medical Research Council, Mars, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Extended bouts of periodic mastication and intermittent energy restriction (IER) may improve cognitive performance in the context of adult hippocampal neurogenesis in an ageing population. A randomised controlled parallel design trial will determine the impact of a 3 month IER diet (2 consecutive days of very low calorie diet and 5 days of normal eating) and a mastication intervention (1 piece of gum chewed for 10 minutes 3 times a day) in comparison to a control on neurogenesis-associated cognitive measures and circulating levels of the anti-ageing protein Klotho.
Detailed Description
Nutrition and human health are strongly related. Altering overabundance through fasting/calorie-restricted diets has profound effects on homeostasis, tissue regeneration, and cancer. Tissue stem cells respond to the physiological changes that occur during fasting through dynamic shifts in their metabolism. Restricting energy intake in mice or introducing mutations in nutrient-sensing pathways can extend lifespans by as much as 50%. Post-mortems reveal that tumours, heart problems, neurodegeneration and metabolic disease are generally reduced/delayed in long-lived mice. Therefore, extending lifespan by energy restriction (ER) also seems to increase 'healthspan', the time lived without chronic age-related conditions. These insights have hardly made a dent in human medicine. Molecular and cellular insights should be established in humans to validate interventions such as ER to delay ageing and associated conditions e.g. cognitive decline (Murphy et al., 2014). Stem cells from the central nervous system also respond to ER. Recently, the Thuret lab have found that ER, in the absence of malnutrition, promotes hippocampal stem cells to proliferate and differentiate into new-born neurons. Because these new postnatal hippocampal neurons have been shown to play a role in cognition, ER also promoted enhanced cognition in rodents (Zainuddin et al., 2012; de Lucia et al., 2017; Thuret et al., 2012). This phenomenon of neurogenesis, the process by which new neurons are generated from neural stem cells, is also occurring in humans (Spalding et al., 2013). It is a tightly regulated process occurring in the mammalian hippocampus which is an environmentally responsive brain structure known to regulate learning, memory and mood. Proposed functions of adult hippocampal neurogenesis (AHN). include enhancing recognition memory, the ability to recognise previously encountered stimuli, and pattern separation, the ability to differentially encode small changes in similar inputs (Clelland et alk., 2009; Sahay et al., 2011). It has been posited that calorie restriction may increase neurogenesis as a "cellular relic" of intermittent feeding patterns during evolution as a response to alternating periods of famine and abundant food (Murphy & Thuret, 2015). Human trials have found significant improvements in verbal recognition memory after 30% reduction in calorie intake (Witte et al., 2009). Also, intermittent fasting in humans has been associated with significant increases in brain activation volume in areas involved in brain function control and plasticity(Belaïch et al., 2016). Food texture and mastication have also been implicated in AHN and cognitive ability (Smith et al., 2016). Decreased mastication due to the removal of molars and edentulism in both humans and animals have a negative impact on AHN and associated cognition. Human populations, in particular, have shown a close association between masticatory function, cognitive status and age-related neurodegeneration in the elderly (Miura et al., 2003). The exact mechanism by which mastication affects cognition is unknown. Research question: In older, overweight participants does IER and/or extended periods of mastication enhance performance inhippocampus-dependent memory tasks and increase anti-ageing marker Klotho? Objectives: A randomised controlled parallel-design trial will determine the impact of an IER diet (2 consecutive days of a very low calorie diet, 5 days of normal healthy eating for 3 months) and/or extended periods of mastication (10 minutes 3 times a day for 3 months) compared to a control group (continued habitual eating behaviour, dietary patterns) on primary outcome variables (MST and Klotho) in older, healthy participants with overweight or class I obesity. To assess the impact of an IER diet and extended periods of mastication on secondary outcomes variables including body composition, mood and sleep. To explore whether extended periods of mastication can be utilised as a weight loss/fasting aid.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aging, Cognitive Decline
Keywords
Intermittent fasting, Adult hippocampal neurogenesis, Mastication, Pattern separation, Recognition memory, Klotho

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
123 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intermittent Energy Restriction
Arm Type
Experimental
Arm Description
Dietary intervention: Intermittent energy restriction
Arm Title
Chewing
Arm Type
Experimental
Arm Description
Mastication intervention: chewing
Arm Title
Chewing + Intermittent Energy Restriction
Arm Type
Experimental
Arm Description
Dietary and mastication intervention: Intermittent energy restriction and chewing
Arm Title
Control
Arm Type
No Intervention
Arm Description
No intervention: Control
Intervention Type
Behavioral
Intervention Name(s)
Intermittent Energy Restriction
Intervention Description
Dietary advice to follow a 5:2 diet.
Intervention Type
Behavioral
Intervention Name(s)
Chewing
Intervention Description
Asked to chew 1 piece of gum for 10 minutes 3 times a day.
Intervention Type
Behavioral
Intervention Name(s)
Chewing + Intermittent Energy Restriction
Intervention Description
Dietary advice to follow a 5:2 diet. Asked to chew 1 piece of gum for 10 minutes 3 times a day.
Primary Outcome Measure Information:
Title
Serum Klotho concentration
Description
Anti-ageing longevity protein
Time Frame
Baseline
Title
Serum Klotho concentration
Description
Anti-ageing longevity protein
Time Frame
Day 42
Title
Serum Klotho concentration
Description
Anti-ageing longevity protein
Time Frame
Day 84
Title
Mnemonic Similarity Task
Description
Neurogenesis-associated cognition
Time Frame
Baseline
Title
Mnemonic Similarity Task
Description
Neurogenesis-associated cognition
Time Frame
Day 42
Secondary Outcome Measure Information:
Title
Body weight
Time Frame
Baseline
Title
Body weight
Time Frame
Day 42
Title
Body weight
Time Frame
Day 84
Title
Body fat percentage
Time Frame
Baseline
Title
Body fat percentage
Time Frame
Day 42
Title
Body fat percentage
Time Frame
Day 84
Title
Body Mass Index
Time Frame
Baseline
Title
Body Mass Index
Time Frame
Day 42
Title
Body Mass Index
Time Frame
Day 84
Title
Waist circumference
Time Frame
Baseline
Title
Waist circumference
Time Frame
Day 42
Title
Waist circumference
Time Frame
Day 84
Title
Hip circumference
Time Frame
Baseline
Title
Hip circumference
Time Frame
Day 42
Title
Hip circumference
Time Frame
Day 84
Title
Patient Health Questionnaire
Description
Questionnaire
Time Frame
Baseline
Title
Patient Health Questionnaire
Description
Questionnaire
Time Frame
Day 42
Title
Patient Health Questionnaire
Description
Questionnaire
Time Frame
Day 84
Title
Zung Self-Rating Anxiety Scale
Description
Questionnaire - Scale can be scored from 20 (normal) to 80 (extreme anxiety levels). The total score is reported.
Time Frame
Baseline
Title
Zung Self-Rating Anxiety Scale
Description
Questionnaire
Time Frame
Day 42
Title
Zung Self-Rating Anxiety Scale
Description
Questionnaire
Time Frame
Day 84
Title
Pittsburgh Sleep Quality Index
Description
Questionnaire
Time Frame
Baseline
Title
Pittsburgh Sleep Quality Index
Description
Questionnaire
Time Frame
Day 42
Title
Pittsburgh Sleep Quality Index
Description
Questionnaire
Time Frame
Day 84
Title
Plasma glucose concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma glucose concentration
Description
Fasting
Time Frame
Day 42
Title
Plasma glucose concentration
Description
Fasting
Time Frame
Day 84
Title
Cholesterol
Description
Fasting
Time Frame
Baseline
Title
Cholesterol
Description
Fasting
Time Frame
Day 42
Title
Cholesterol
Description
Fasting
Time Frame
Day 84
Title
Triglycerides
Description
Fasting
Time Frame
Baseline
Title
Triglycerides
Description
Fasting
Time Frame
Day 42
Title
Triglycerides
Description
Fasting
Time Frame
Day 84
Title
High Density Lipoprotein
Description
Fasting
Time Frame
Baseline
Title
High Density Lipoprotein
Description
Fasting
Time Frame
Day 42
Title
High Density Lipoprotein
Description
Fasting
Time Frame
Day 84
Title
Low Density Lipoprotein
Description
Fasting
Time Frame
Baseline
Title
Low Density Lipoprotein
Description
Fasting
Time Frame
Day 42
Title
Low Density Lipoprotein
Description
Fasting
Time Frame
Day 84
Title
Total/HDL Cholesterol Ratio
Description
Fasting
Time Frame
Baseline
Title
Total/HDL Cholesterol Ratio
Description
Fasting
Time Frame
Day 42
Title
Total/HDL Cholesterol Ratio
Description
Fasting
Time Frame
Day 84
Title
Plasma adiponectin concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma adiponectin concentration
Description
Fasting
Time Frame
Day 42
Title
Plasma adiponectin concentration
Description
Fasting
Time Frame
Day 84
Title
Plasma leptin concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma leptin concentration
Description
Fasting
Time Frame
Day 42
Title
Plasma leptin concentration
Description
Fasting
Time Frame
Day 84
Title
Plasma beta-hydroxybutrate concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma beta-hydroxybutrate concentration
Description
Fasting
Time Frame
Day 42
Title
Plasma beta-hydroxybutrate concentration
Description
Fasting
Time Frame
Day 84
Title
Plasma total cholesterol concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma total cholesterol concentration
Description
Fasting
Time Frame
Day 42
Title
Plasma total cholesterol concentration
Description
Fasting
Time Frame
Day 84
Title
Plasma low density lipoprotein (LDL) cholesterol concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma LDL cholesterol concentration
Description
Fasting
Time Frame
Day 42
Title
Plasma LDL cholesterol concentration
Description
Fasting
Time Frame
Day 84
Title
Plasma high density lipoprotein (HDL) cholesterol concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma HDL cholesterol concentration
Description
Fasting
Time Frame
Day 42
Title
Plasma HDL cholesterol concentration
Description
Fasting
Time Frame
Day 84
Title
Plasma triglyceride concentration
Description
Fasting
Time Frame
Baseline
Title
Plasma triglyceride concentration
Description
Fasting
Time Frame
Day 42
Title
Plasma triglyceride concentration
Description
Fasting
Time Frame
Day 84
Title
Plasma total cholesterol:HDL cholesterol ratio
Description
Fasting
Time Frame
Baseline
Title
Plasma total cholesterol:HDL cholesterol ratio
Description
Fasting
Time Frame
Day 42
Title
Plasma total cholesterol:HDL cholesterol ratio
Description
Fasting
Time Frame
Day 84
Other Pre-specified Outcome Measures:
Title
Adverse events
Time Frame
Baseline until endpoint: Day 84

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male and female subjects. 60+ years of age at the time of consent. BMI 25-35. Exclusion Criteria: Subject is unable to understand the participant information sheet. Subject is unable to understand and/or completely perform the cognitive testing. Chews more than 3 sticks of gum per month, including nicotine replacement gum. Unable to provide written informed consent. Impaired vision that is not corrected. Does not agree to maintain their habitual exercise routine. Is not in general good health on the basis of medical history. Unwilling to chew gum for 3 times a day for 12 weeks. Unwilling to maintain an intermittent fasting diet regime. Unwilling to have blood taken. History of or are currently diagnosed with a significant psychiatric disorder (e.g. schizophrenia, anxiety, PTSD). Subject has any neurological disorder that could produce cognitive deterioration (e.g. Alzheimer's disease, Parkinson's disease, stroke). History of traumatic brain injury, stroke or any other medical conditions causing cognitive impairment. Has uncontrolled epilepsy or is prone to fainting. Participated in a weight management drug trial in previous 3 months. Has undergone bariatric surgery. Known or suspected of alcohol abuse defined as >14 drinks per week (1 drink = 1 pint of beer, 1 large glass of wine or 50ml spirit). Gastrointestinal or liver disease. Subject has a sleep disorder or an occupation where sleep during the overnight hours is irregular. Subjects taking the following prescription medications: Donepezil (Aricept), Galantamine (Reminyl), Rivastigmine (Exelon), Tacrine (Cognex), Bethanechol (Urecholine), Memantine (Namenda) Selegiline (Eldepryl) or any other medication for cognitive impairment. Subject has a known sensitivity to the study product. Individual has a condition the chief investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, might confound the interpretation of study results or put the subject at undue risk.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sandrine Thuret, PhD
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Wendy L Hall, PhD
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Diabetes & Nutritional Sciences Division, King's College London, Franklin-Wilkins Building, 150 Stamford St
City
London
State/Province
England
ZIP/Postal Code
SE1 9NH
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
24900924
Citation
Murphy T, Dias GP, Thuret S. Effects of diet on brain plasticity in animal and human studies: mind the gap. Neural Plast. 2014;2014:563160. doi: 10.1155/2014/563160. Epub 2014 May 12.
Results Reference
background
PubMed Identifier
19171901
Citation
Witte AV, Fobker M, Gellner R, Knecht S, Floel A. Caloric restriction improves memory in elderly humans. Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1255-60. doi: 10.1073/pnas.0808587106. Epub 2009 Jan 26.
Results Reference
background
PubMed Identifier
23254518
Citation
Akazawa Y, Kitamura T, Fujihara Y, Yoshimura Y, Mitome M, Hasegawa T. Forced mastication increases survival of adult neural stem cells in the hippocampal dentate gyrus. Int J Mol Med. 2013 Feb;31(2):307-14. doi: 10.3892/ijmm.2012.1217. Epub 2012 Dec 18.
Results Reference
background
Citation
Smith, N., Miquel-Kergoat, S. & Thuret, S., 2016. The impact of mastication on cognition: Evidence for intervention and the role of adult hippocampal neurogenesis. Nutrition and Aging, 3(2-4), pp.115-123
Results Reference
background

Learn more about this trial

Intermittent Energy Restriction and Chewing on Neural Stem Cell Ageing and Adult Hippocampal Neurogenesis Associated Cognition

We'll reach out to this number within 24 hrs